# US 2024/0002789 A1 · Skin spheroids and process of preparation and use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0002789 A1
- Document ID: US20240002789A1
- Status: Published application
- Kind: A1
- Application number: 18/037,740
- Filed: 2021-11-05
- Published: 2024-01-04
- Earliest claimed: 2020-11-20
- Assignees: The Governing Council of the University of Toronto; BASF SE
- Applicants: The Governing Council of The University of Toronto; BASF SE
- Inventors: Eugenia KUMACHEV; Valerie ANDRE; Ted W. DEISENROTH; Zhengkun CHEN
- Web page: https://patentgrep.com/patent/US20240002789A1

## CPC

- B01J 13/046: {combined with gelification or coagulation}
- C12N 5/0629: {Keratinocytes; Whole skin}
- A61K 35/36: Skin; Hair; Nails; Sebaceous glands; Cerumen; Epidermis; Epithelial cells; Keratinocytes; Langerhans cells; Ectodermal cells (islets of Langerhans A61K35/39)
- C12M 23/12: {Well or multiwell plates (C12M25/04 takes precedence)}
- C12M 23/16: {Microfluidic devices; Capillary tubes (integrated microfluidic structures B01L3/5027; microreactors B01J19/0093)}
- C12N 2513/00: 3D culture
- B01J: CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12M: APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; {APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS}

## Abstract

Disclosed are embodiments of a multicellular spheroid, including a core containing first skin cells; the core can have an average diameter of about 10 μm to about 900 μm. The multicellular spheroid may further include a shell overlaying the core, the shell having second skin cells. Further disclosed are systems containing such multicellular spheroids and methods of preparation and use of multicellular spheroids.

## Claims

### Claim 1

A multicellular spheroid, comprising:
a core comprising first skin cells, wherein the core has an average diameter of about 10 μm to about 900 μm; and
a shell overlaying the core, the shell comprising second skin cells.

### Claim 2 (depends on 1)

The multicellular spheroid of claim 1, wherein the first skin cells and the second skin cells independently comprise at least one of dermis cells, epidermis cells or hypodermis cells.

### Claim 3 (depends on 2)

The multicellular spheroid of claim 2, wherein the dermis cells comprise one or more of dermal fibroblasts, myofibroblasts, keloid fibroblasts, dermal papilla cells, sebocytes or dermal dendritic cells.

### Claim 4 (depends on 2, 3)

The multicellular spheroid of claim 2 or 3, wherein the epidermis cells comprise one or more of keratinocytes, epidermal stem cells, myoepithelial cells, melanocytes, Langerhans cells or Merkel cells.

### Claim 5 (depends on 2, 3, 4)

The multicellular spheroid of any one of claims 2 to 4, wherein the hypodermis cells comprise one or more of adipocytes, adipose derived stem cells, tenocytes, smooth muscle cells, gland stem cells or myoblasts.

### Claim 6

The multicellular spheroid of any preceding claim, wherein the first skin cells comprise human dermal fibroblasts and the second skin cells comprise keratinocytes.

### Claim 7

The multicellular spheroid of any preceding claim, wherein the shell has an average thickness of about 1 μm to about 30 μm.

### Claim 8

The multicellular spheroid of any preceding claim, wherein the first skin cells form an aggregate.

### Claim 9

The multicellular spheroid of any preceding claim, wherein the first skin cells are within a first hydrogel.

### Claim 10

The multicellular spheroid of any preceding claim, wherein the second skin cells are within a second hydrogel.

### Claim 11

The multicellular spheroid of any preceding claim, wherein the shell is adhered to the core.

### Claim 12

The multicellular spheroid of any preceding claim, wherein the first skin cells are contracted.

### Claim 13

A multicellular spheroid system, comprising:
a plurality of multicellular spheroids, each multicellular spheroid comprising:
a core comprising first skin cells, wherein the core has an average diameter of about 10 μm to about 900 μm; and
a shell overlaying the core, the shell comprising second skin cells,
wherein the plurality of multicellular spheroids are arranged in an array of microwells.

### Claim 14 (depends on 13)

The system of claim 13, wherein the array of microwells is within a microfluidic device.

### Claim 15 (depends on 13, 14)

The system of claim 13 or 14, wherein each microwell has a cylindrical shape.

### Claim 16 (depends on 13, 14, 15)

The system of any one of claims 13 to 15, wherein each microwell has a diameter of about 50 μm to about 1000 μm.

### Claim 17 (depends on 13, 14, 15, 16)

The system of any one of claims 13 to 16, wherein the array of microwells is connected with a supplying channel.

### Claim 18 (depends on 13, 14, 15, 16, 17)

The system of any one of claims 13 to 17, wherein each of the plurality of multicellular spheroids has an average diameter that is within about ±1 μm to about ±10 μm of each other.

### Claim 19 (depends on 13, 14, 15, 16, 17, 18)

The system of any one of claims 13 to 18, wherein each of the plurality of multicellular spheroids has a spherical shape, a cylindrical shape or a disc shape.

### Claim 20

A microfluidic-based process for preparing multicellular spheroids, comprising:
flowing a first skin cell-laden suspension into microwells and forming cell-laden droplets and inducing gelation to form gelled cell-laden droplets;
supplying a first aqueous culture medium to the microwells to induce aggregation of the gelled cell-laden droplets and form compacted spheroids;
flowing a second skin cell-laden suspension through the microwells to surround the compacted spheroids and induce gelation; and
supplying a second aqueous culture medium to the microwells, wherein the second aqueous culture medium induces formation of the multicellular spheroids, each of the multicellular spheroids comprising a core comprising first skin cells and a shell comprising second skin cells.

### Claim 21 (depends on 20)

The process of claim 20, wherein the first skin cell-laden suspension comprises first skin cells suspended in an aqueous fluid, or
wherein the first skin cell-laden suspension comprises first skin cells suspended in a hydrogel precursor solution.

### Claim 22 (depends on 20, 21)

The process of claim 20 or 21, wherein preparing the first skin cell-laden suspension comprises:
combining first skin cells with a first physiologically compatible hydrogel precursor solution.

### Claim 23 (depends on 22)

The process of claim 22, wherein the first physiologically compatible hydrogel comprises constituents that provide a biomimetic extracellular environment to assist in formation of the compact spheroids from the first cells and to support metabolic activity of the compact spheroids.

### Claim 24 (depends on 22, 23)

The process of claim 22 or 23, wherein the first physiologically compatible hydrogel precursor solution comprises about 0.3 wt % to about 2 wt %, or about 0.5 wt % aldehyde-functionalized cellulose nanocrystals (a-CNCs) and about 0.6 wt % to about 4 wt %, or about 1.5 wt % gelatin.

### Claim 25 (depends on 20, 21, 22, 23, 24)

The process of any one of claims 20 to 24, further comprising:
flowing the first cell-laden suspension through microchannels into the microwells.

### Claim 26 (depends on 20, 21, 22, 23, 24, 25)

The process of any one of claims 20 to 25, wherein the second skin cell-laden suspension comprises second skin cells suspended in an aqueous fluid, or
wherein the second skin cell-laden suspension comprises second skin cells suspended in a hydrogel precursor solution.

### Claim 27 (depends on 20, 21, 22, 23, 24, 25, 26)

The process of any one of claims 20 to 26, wherein preparing the second skin cell-laden suspension comprises:
combining second skin cells with a second physiologically compatible hydrogel precursor solution.

### Claim 28 (depends on 27)

The process of claim 27, wherein the second physiologically compatible hydrogel comprises constituents that provide a biomimetic extracellular environment to assist in formation of the shell containing the second skin cells surrounding the compact spheroids and to support metabolic activity of the shell and maintain structural integrity of the hybrid multicellular spheroids.

### Claim 29 (depends on 27, 28)

The process of claim 27 or 28, wherein the second physiologically compatible hydrogel precursor solution comprises about 0.3 wt % to about 2 wt %, or about 1.5 wt % aldehyde-functionalized cellulose nanocrystals (a-CNCs) and about 0.6 wt % to about 4 wt %, or about 3.0 wt % gelatin.

### Claim 30 (depends on 20, 21, 22, 23, 24, 25, 26, 27, 28, 29)

The process of any one of claims 20 to 29, further comprising:
flowing the second skin cell-laden suspension through microchannels into the microwells.

### Claim 31 (depends on 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31)

The process of any one of claims 20 to 31, wherein forming the cell-laden droplets comprises a self-digitization process to fill each microwell with the first skin cell-laden suspension.

### Claim 32 (depends on 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32)

The process of any one of claims 20 to 32, wherein the first aqueous culture medium is conFIG.d to induce contraction of the cell-laden droplets to form the compacted spheroids.

### Claim 33 (depends on 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33)

The process of any one of claims 20 to 33, wherein a surface of each of the compacted spheroids comprises free space between the surface and walls of the microwells.

### Claim 34 (depends on 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33)

The process of any one of claims 20 to 33, further comprising:
pre-wetting the microwells with a fluid immiscible to the first skin cell-laden suspension.

### Claim 35 (depends on 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34)

The process of any one of claims 20 to 34, further comprising:
after forming the gelled cell-laden droplets, flowing a fluid immiscible to the first skin cell-laden suspension through microchannels connected with the microwells for displacing any extra first skin cell-laden suspension located therein,
after forming the compacted spheroids, flowing a fluid immiscible to the first aqueous culture medium through microchannels connected with the microwells for displacing any extra first aqueous culture medium located therein, and
after flowing the second skin cell-laden suspension through the microwells, flowing a fluid immiscible to the second skin cell-laden suspension through microchannels connected with the microwells for displacing any extra second skin cell-laden suspension located therein.

### Claim 36 (depends on 34, 35)

The process of claim 34 or 35, wherein the immiscible fluid comprises at least one of a biocompatible oil, an organic liquid, an organic oil, or a fluorinated oil.

### Claim 37 (depends on 36)

The process of claim 36, wherein the fluorinated oil comprises about 0.1 wt % to about 1.0 wt %, or about 0.5 wt % of a fluorosurfactant.

### Claim 38 (depends on 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37)

The process of any one of claims 20 to 37, wherein one or more process steps is conducted at a temperature of about 37° C. under an atmosphere of about 5% CO2.

### Claim 39 (depends on 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34)

The process of any one of claims 20 to 34, wherein each of the microwells has a diameter of about 50 μm to about 1000 μm.

### Claim 40 (depends on 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39)

The process of any one of claims 20 to 39, wherein the first skin cells and the second skin cells independently comprises at least one of dermis cells, epidermis cells or hypodermis cells.

### Claim 41 (depends on 40)

The process of claim 40, wherein the dermis cells comprise one or more of dermal fibroblasts, myofibroblasts, keloid fibroblasts, dermal papilla cells, sebocytes or dermal dendritic cells.

### Claim 42 (depends on 40)

The process of claim 40, wherein the epidermis cells comprises one or more of keratinocytes, epidermal stem cells, myoepithelial cells, melanocytes, Langerhans cells or Merkel cells.

### Claim 43 (depends on 40)

The process of claim 40, wherein the hypodermis cells comprise one or more of adipocytes, adipose derived stem cells, tenocytes, smooth muscle cells, gland stem cells or myoblasts.

### Claim 44 (depends on 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43)

The process of any one of claims 20 to 43, wherein the first skin cells are human dermal fibroblasts, and the second skin cells are human keratinocytes cells.

### Claim 45 (depends on 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44)

The process of any one of claims 20 to 44, wherein the first skin cell-laden suspension comprises about 5×103 cells/μL to about 5×106 cells/μL, or about 4.9×105 cells/μL dermal fibroblast cells.

### Claim 46 (depends on 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45)

The process of any one of claims 20 to 45, wherein the second skin cell-laden suspension has a cell/gel mass ratio of about 100:0 to about 50:50, or about 75:25.

### Claim 47 (depends on 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46)

The process of any one of claims 20 to 46, wherein the first skin cell-laden suspension flows from a preparation reservoir through microchannels to the microwells at a flow rate of about 0.01 mL/hr to about 0.30 mL/hr.

### Claim 48 (depends on 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47)

The process of any one of claims 20 to 47, wherein the second skin cell-laden suspension flows from a preparation reservoir through microchannels to the microwells at a flow rate of about 0.1 mL/hr to about 1 mL/hr.

### Claim 49 (depends on 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48)

The process of any one of claims 20 to 48, wherein at least one of the first aqueous culture medium or the second aqueous culture medium flows from a preparation reservoir through microchannels to the microwells at a flow rate of about 0.001 mL/hr to about 0.5 mL/hr.

### Claim 50 (depends on 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49)

Multicellular spheroids comprising a core comprising first skin cells and a shell comprising second skin cells produced by the process of any one of claims 20 to 49.
